Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast

Zoran Gatalica, Semir Vranic, Anatole Ghazalpour, Joanne Xiu, Idris Tolgay Ocal, John McGill, Ryan P. Bender, Erin Discianno, Aaron Schlum, Souzan Sanati, Juan Palazzo, Sandeep Reddy, Barbara Pockaj

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Malignant phyllodes tumor is a rare breast malignancy with sarcomatous overgrowth and with limited effective treatment options for recurrent and metastatic cases. Recent clinical trials indicated a potential for anti-angiogenic, anti-EGFR and immunotherapeutic approaches for patients with sarcomas, which led us to investigate these and other targetable pathways in malignant phyllodes tumor of the breast. Thirty-six malignant phyllodes tumors (including 8 metastatic tumors with two cases having matched primary and metastatic tumors) were profiled using gene sequencing, gene copy number analysis, whole genome expression, and protein expression. Whole genome expression analysis demonstrated consistent over-expression of genes involved in angiogenesis including VEGFA, Angiopoietin-2, VCAM1, PDGFRA, and PTTG1. EGFR protein overexpression was observed in 26/27 (96%) of cases with amplification of the EGFR gene in 8/24 (33%) cases. Two EGFR mutations were identified including EGFRvIII and a presumed pathogenic V774M mutation, respectively. The most common pathogenic mutations included TP53 (50%) and PIK3CA (15%). Cases with matched primary and metastatic tumors harbored identical mutations in both sites (PIK3CA/KRAS and RB1 gene mutations, respectively). Tumor expression of PD-L1 immunoregulatory protein was observed in 3/22 (14%) of cases. Overexpression of molecular biomarkers of increased angiogenesis, EGFR and immune checkpoints provides novel targeted therapy options in malignant phyllodes tumors of the breast.

Original languageEnglish (US)
Pages (from-to)1707-1716
Number of pages10
JournalOncotarget
Volume7
Issue number2
DOIs
StatePublished - 2016

Keywords

  • Biomarkers
  • Breast
  • Fibroepithelial tumors
  • Malignant phyllodes tumor
  • Molecular profiling

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast'. Together they form a unique fingerprint.

  • Cite this

    Gatalica, Z., Vranic, S., Ghazalpour, A., Xiu, J., Ocal, I. T., McGill, J., Bender, R. P., Discianno, E., Schlum, A., Sanati, S., Palazzo, J., Reddy, S., & Pockaj, B. (2016). Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast. Oncotarget, 7(2), 1707-1716. https://doi.org/10.18632/oncotarget.6421